After hiring of Peter Marks, Eli Lilly’s chief scientific officer isn’t fazed by revolving doors

Taking stock of the drug industry, from the lab to the medicine chest

October 16, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Jeff Pinette for STAT STAT+ | After hiring of a former top FDA official, Eli Lilly's chief scientific officer isn't fazed by revolving doors "What kind of society would we live in if government jobs were a one-way door?" asked Eli Lilly's chief scientific officer, Dan Skovronsky. By Ed Silverman STAT+ | Funding cuts threaten new generation of cancer immunotherapies, researcher says "We're so close." Dr. Miriam Merad says NIH cuts could derail life-saving cancer research just as scientists close in on new immune cell–based therapies. By Elizabeth Cooney Baby KJ's doctors will ask FDA this winter to OK a clinical trial of pioneering gene editing approach A bouncing Baby KJ, resplendent in a toddler tuxedo, wows crowd at STAT Summit as experts discuss scaling up personalized medicine By Megan Molteni Adobe STAT+ | Medicare backs off plan to pause doctor payments amid shutdown Late Wednesday, Medicare said it wouldn't enact a broad pause on payments to clinicians, reversing an earlier statement. By Daniel Payne and Tara Bannow

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser